All News

Save the date! RheumNow will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/rDMFH3wlbc
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Dr. Quotes (11.8.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.

Read Article
microbes.jpg

Gut microbiome changes linked to onset of RA

d EurekAlert!

Changes in the make-up of the gut microbiome are linked to the onset of clinically evident rheumatoid arthritis in those at risk of the disease because of genetic, environmental, or immunological factors, suggests research published online in the 

Read Article
bone%20dense.jpg (keep)

Genes Linking Rheumatoid Arthritis and Osteoporosis

d EurekAlert!

Rheumatoid arthritis is a common disease affecting an estimated 17 million people worldwide. The disease is caused by immune cells attacking the joints and can result in pain, swelling, and damage to the cartilage and bone.

Read Article
COVID.virus_.corona.jpg (keep)

COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders

d Jack Cush, MD

A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.

Read Article
Study of at-risk & early RA Synovium suggests an early pathogenic myeloid signature (IL-1B+CCL20+ & SPP1+MT2A+ macrophage clusters) before disease onset. These display heightened CD40 expression, capable of shaping stromal cell responses https://t.co/CYmb1ro9g9 https://t.co/9pXbqHaQ2G

Links:

Dr. John Cush RheumNow ( View Tweet)
Nationwide Readmissions Database (NRD) study of 133,187 #RA pts found that 48% were "frail". Hospital readmissions were significantly higher in the RA frail pts (57% vs 31%), & hospitalized, frail patients also had significantly higher mortality (3.36% vs 0.39%) & longer LOS… https://t.co/6lF4wrC87B https://t.co/mWJGIPbEjc
Dr. John Cush RheumNow ( View Tweet)
refridge.crisper.storage.jpg

EULAR Review of Lifestyle Improvements for Rheumatic Patients

d Jack Cush, MD

A EULAR taskforce has evaluated the effect of lifestyle behaviors in rheumatic and musculoskeletal diseases (RMDs) and concluded that there is moderate evidence for a small benefit for certain dietary components, but overall, high-level evidence regarding dietary exposures on outcomes in RMDs is lacking.

Read Article
An 11 yr study of 2187 #RA pts Rx w/ 3068 treatment courses of biologics or JAki, found 275 new cases of #CKD . Compared w/ CTLA4-Ig, TNFi significantly lower CKD rates (HR 0.67), whiile JAKi higher CKD rates (HR 2.16). https://t.co/2Y5BuDzJRs https://t.co/e81lOhOMjX

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/uKc14y1fOm
Dr. John Cush RheumNow ( View Tweet)
Overview of IL-23 inhibition for chronic inflammatory disease (partial read) from Lancet. Started with targeting the p40 subunit shared between IL-12 & IL-23A. Now we have specific inhibitors of the p19 protein of IL-23A. These agents are superior to TNFi in plaque… https://t.co/ud61WLgWs2 https://t.co/fQ7WhLyrsi
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine effects studied in 30pts (23 RA, 7SLE). Results did not support that HCQ may reduce CV risk - Arterial stiffness was not affected by HCQ, HCQ modestly lowered HbA1c & lipids - yet HCQ has been shown to reduced CV risk in observational studies… https://t.co/n283HwvRm4 https://t.co/lQN342uevy
Dr. John Cush RheumNow ( View Tweet)
Are seronegative RA and clinically suspect arthralgia pts represented in randomized clinical trials? Most RCTs (And prevention trials) predominantly enroll seropositive patients. - potentially overlooking seronegative individuals with arthralgia-at-risk. https://t.co/D1eOApgn1p https://t.co/IBCNtNW8uI

Links:

Dr. John Cush RheumNow ( View Tweet)
Filgotinib Efficacy and Safety - 3 Years Later Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration trial participants who continued in… https://t.co/eABIG1Kal6 https://t.co/7ZphZALniE
Dr. John Cush RheumNow ( View Tweet)
RA.Ow02.jpg

Filgotinib Efficacy and Safety - 3 Years Later

d MedPage Today

Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration trial participants who continued in a long-term extension study, researchers said.

Read Article
STAR study shows 102 RA pts in LDA > 3 mos & pred 5 mg/d did equally well with either prednisone taper or changing to hydrocortisone 20 mg/d and taperin HC. At 12 mos both wer able to D/C GC (55% HC vs 47% pred tapering; p=0.4). https://t.co/C6YTGiF0pN

Links:

Dr. John Cush RheumNow ( View Tweet)

Blue Collar Arthritis (10.25.2024) Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow. https://t.co/INcke6eLLC https://t.co/TGyxzmCrjv

Links:

Dr. John Cush RheumNow ( View Tweet)
Airway Dz in RA (w/o ILD dx) studied in 188 pts. Airways obst. in 21% by PFTs (assoc w/ older, male, smoking). CXR abnl in 61%, (55% bronchial thickening, 12% bronchiectasis), esp in RF+. Quant CT scan measures correlated w/ respiratory symptoms https://t.co/In1sxLZQRm https://t.co/anmUNGuby8

Links:

Dr. John Cush RheumNow ( View Tweet)
Pain Relief in RA: JAK Better than TNF Inhibitors? Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest. https://t.co/olXQMGm2h8 https://t.co/Em7ydT33Ui

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read review on the detection & management of #ILD in Autoimmune Dz (AID). - AID at risk for ILD should be screened with hi-res CT Scan - ILD should be monitored closely w/ PFTs - Multidisciplinary Rx includes immunosuppressives & antifibrotics https://t.co/X6Feor2wF5 https://t.co/Z2WBWL3q1W

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.